Provectus Biopharmaceuticals (NYSEMKT:PVCT) resumed trading today, but shareholders probably wished it was still frozen from last Friday. Shares collapsed a startling 63% on news that the FDA would not grant a breakthrough designation to Provectus' melanoma drug PV-10.

In this episode of Market Checkup, The Motley Fool's health-care-focused investing show, analysts David Williamson and Michael Douglass discuss the controversy surrounding Provectus, the increasing competition for its mid-stage drug, and whthere the stock is a bad news buy.

Watch and find out.

 

  

David Williamson, Michael Douglass, and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.